Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma.

CONCLUSIONS: These data demonstrated a DCE-MRI marker, Ktrans, can detect early responses to stroma-directed drug and reveal the sustained effect of combination treatment (PEGPH20+ gemcitabine). PMID: 30587546 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30587546?dopt=Abstract

Source: Clinical Cancer Research - December 26, 2018 Category: Cancer & Oncology Authors: Cao J, Pickup S, Clendenin C, Blouw B, Choi H, Kang D, Rosen M, O'Dwyer PJ, Zhou R Tags: Clin Cancer Res Source Type: research